220 results
6-K
EX-99.2
THTX
Theratechnologies Inc.
15 Apr 24
Notice of Annual Meeting of Shareholders
9:31am
activities;
market capitalization between $100 million to $3 billion;
revenue, pipeline status, research and development expenses, number of employees, cash … to research and development activities;
Canvassing the potential acquisition or in-licensing of new products and supervising the negotiation of agreements
6-K
EX-99.2
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
of high unmet need, including innovative medicines in oncology and NASH. The Company’s research & development activities also works on extending … to the Phase 1 clinical trial and to other research and development activities related to its SORT1+Technology™ platform. Of this amount, $2,500,000
6-K
EX-99.1
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
-month periods ended February 29, 2024 and February 28, 2023
(Unaudited)
Note
Revenue
Operating expenses
Cost of goods sold
Research and development
6-K
EX-99.1
dro3y3l7gms9qe
6 Nov 23
Investor Rights Agreement
12:28pm
SUPPL
5ir0w
26 Oct 23
Supplemental materials (foreign)
9:13pm
SUPPL
jouyi g7fut9
25 Oct 23
Supplemental materials (foreign)
6:56pm
6-K
EX-99.1
t1hqy7
26 Sep 23
Interim Consolidated Financial Statements
8:00am
6-K
EX-99.2
8or33ty9qe
26 Sep 23
Interim Consolidated Financial Statements
8:00am
6-K
EX-99.2
4hn3fz q8z
12 Jul 23
Interim Consolidated Financial Statements
8:02am
6-K
EX-99.1
ngzhrmjfc 3t7w7v
12 Jul 23
Interim Consolidated Financial Statements
8:02am
6-K
EX-99.1
b35si hb2yoq10
12 Jul 23
Theratechnologies Reports Second Quarter 2023
8:00am
6-K
EX-99.1
c6g91i4kmzbplet d72
2 Jun 23
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
1:02pm
6-K
EX-99.2
a66ma13 st8cago
13 Apr 23
Notice of Annual Meeting of Shareholders
8:01am
6-K
EX-99.1
d4cnv
12 Apr 23
Interim Consolidated Financial Statements
8:00am
6-K
EX-99.2
6cnirkmh upc3dgcr7
12 Apr 23
Interim Consolidated Financial Statements
8:00am
6-K
EX-99.1
pb8wswtgdad
2 Dec 22
Theratechnologies Announces Update from Ongoing TH1902 Study
12:57pm